What happened with NAGE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Niagen Bioscience sells finished Tru Niagen dietary supplements to consumers and distribution partners. These products generate most of its revenue, reaching buyers through its own online stores, third-party marketplaces, retailers and international partners. The business depends heavily on demand for Tru Niagen and on marketing that attracts and retains customers at a manageable cost.
Its next-largest business sells Niagen as an ingredient. Consumer-product manufacturers buy the food-grade version for supplements and foods. U.S. FDA-registered outsourcing facilities and overseas compounding pharmacies buy the pharmaceutical-grade version and prepare intravenous and injectable formulations. Niagen Bioscience supplies the ingredient rather than administering treatments; these uses are subject to prescription requirements and regulatory limits, including FDA rules on which bulk ingredients U.S. outsourcing facilities may use. Separately, its pharmaceutical research targets potential rare-disease treatments but generates no commercial revenue.
The company relies on W.R. Grace as its sole supplier of the core ingredient and on outside manufacturers for finished supplements. Grace’s patents limit alternative sourcing, and the exclusive supply agreement requires Niagen Bioscience to purchase minimum quantities.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Niagen Bioscience depends on demand for Tru Niagen and its proprietary ingredient, whose exclusive manufacturer W.R. Grace is a key supplier missing from this list.
FitLife Brands competes with Niagen Bioscience for wellness consumers buying branded general-health and targeted nutritional supplements online and through specialty retailers. Watch FitLife’s online supplement sales, where it reaches the same type of shoppers behind much of Tru Niagen’s 2025 sales growth.
USANA competes with Niagen Bioscience for consumers’ discretionary wellness spending on proprietary, science-backed nutritional supplements, although their sales channels differ. Watch USANA’s core nutritional active customers—buyers for personal use or resale who purchased within the latest three months—as a sign of demand among those supplement consumers.
Mannatech competes with Niagen Bioscience’s Tru Niagen for consumers seeking nutritional support for healthy aging, selling proprietary wellness and anti-aging supplements mainly through networks of sellers. Watch its wellness supplement offerings, including Ambrotose, a patented blend intended to support the immune system, for how it distinguishes its products to those consumers.
Niagen Bioscience, Inc. earningsThis company
Niagen Bioscience's report will show whether Tru Niagen consumer products and ingredient sales keep growing, and whether that growth turns into operating profit.
Read Consumer Products and Ingredients sales alongside each segment's operating income. If sales grow in both and operating income keeps pace, growth is coming from more than one part of the business and is reaching profit. If Consumer Products sales slow, or sales rise while operating income lags, the core product's demand may be weakening or costs may be absorbing the gains.
FitLife Brands, Inc. earningsFTLF
FitLife Brands' report will show how shoppers are responding to branded supplements online, a useful read-through for Niagen Bioscience's Tru Niagen e-commerce business.
Watch FitLife Brands' online supplement sales. Growth would suggest online shoppers are still buying branded supplements, a supportive demand backdrop for Niagen Bioscience's Tru Niagen e-commerce business. A decline would point to possible pressure among overlapping shoppers, but the companies sell different products and use different channels, so it would not establish that Niagen's sales moved the same way.
